Design of metallocenic drugs.

Studies on structure-activity relationships of organometallic anticancer drugs are reviewed. Three methods for the development of new structures are described. Drug targeting: platinum complexes with oestrophilic ligands were synthesized, and the endocrine and cytostatic effects are discussed. Quantitative structure-activity relationship determination is presented as a rational method for the design of active compounds. The molecular modelling technique is used for the analysis of molecular properties.